Cardiac troponin (cTn) is the recommended and preferred biomarker for diagnosing acute myocardial infarction.1,2 The use of high-sensitivity cTn assays and broad testing across various clinical scenarios has led to a progressive increase in the number of patients displaying increased cTn concentrations >99th percentile in the settings of acute and chronic pathologies other than type 1 myocardial infarction. Several studies suggest that most increased levels of cTn in contemporary practice are due to either type 2 myocardial infarction or myocardial injury.